Viking Therapeutics Secures Manufacturing Might Ahead of Pivotal Data

Viking Therapeutics secures multi-ton manufacturing capacity for its GLP-1 drug candidate VK2735, funding a $150M build-out ahead of pivotal Q3 2026 clinical trial results.

While Viking Therapeutics shares have faced a challenging opening to 2026, the company's leadership is laying extensive groundwork behind the scenes. In a forward-looking move, the biotech firm has locked in significant production capacity for its weight-loss drug candidate, VK2735, well ahead of receiving the crucial clinical data required for potential approval.

A Stock in Holding Pattern

The equity has retreated approximately eight percent since January, recently trading around the $32 level. This pullback reflects a cautious, wait-and-see approach from the market as investors carefully assess the risk profile of a pre-revenue company. The entire investment thesis hinges on a series of imminent clinical milestones.

The most data-intensive period in the company’s history is slated for the third quarter of 2026, centered on the GLP-1 medication VK2735. Viking anticipates results from a maintenance study investigating whether the therapy can be administered on a monthly schedule. Concurrently, management plans to initiate two Phase 3 trials for an oral version of the drug. These tablet studies are projected to be substantially less expensive and will enroll 75% fewer patients than the ongoing injectable "VANQUISH" program. The VANQUISH trial is currently recruiting participants, building on prior Phase 2 data that demonstrated an average weight reduction of 14.7%.

Building a Foundation for Scale

The scale of Viking's preparatory efforts for a potential commercial launch is notable. The company has established comprehensive, multi-year manufacturing agreements with contract development and manufacturing organizations (CDMOs) CordenPharma and Catalent. These pacts secure annual production capacity for multiple tons of the pharmaceutical active ingredient.

Furthermore, CordenPharma is dedicating capacity for up to 100 million auto-injectors and over one billion tablets per year. To guarantee this production security, Viking will make advance payments totaling $150 million between 2025 and 2028. Catalent will provide complementary fill-finish and secondary manufacturing services to enable large-scale production.

Financially, Viking appears well-equipped for this preparatory offensive. Its balance sheet held cash reserves of $706 million at the end of 2025. Management has confirmed these funds are sufficient to support operations through the upcoming critical milestones. The clinical results expected in Q3 2026 now form the essential prerequisite to fundamentally justify the already-funded build-out of this manufacturing infrastructure.